Dramane I. Lainé

788 total citations
29 papers, 528 citations indexed

About

Dramane I. Lainé is a scholar working on Molecular Biology, Organic Chemistry and Physiology. According to data from OpenAlex, Dramane I. Lainé has authored 29 papers receiving a total of 528 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 10 papers in Organic Chemistry and 6 papers in Physiology. Recurrent topics in Dramane I. Lainé's work include Receptor Mechanisms and Signaling (7 papers), Asymmetric Synthesis and Catalysis (6 papers) and Asthma and respiratory diseases (6 papers). Dramane I. Lainé is often cited by papers focused on Receptor Mechanisms and Signaling (7 papers), Asymmetric Synthesis and Catalysis (6 papers) and Asthma and respiratory diseases (6 papers). Dramane I. Lainé collaborates with scholars based in United States, United Kingdom and France. Dramane I. Lainé's co-authors include Jakob Busch‐Petersen, Darren J. Dixon, Richard C. D. Brown, Yulai Hu, Nicola J. Adderley, Morifumi Fujita, Steven V. Ley, James J. Foley, M Salmon and Mark A. Luttmann and has published in prestigious journals such as Angewandte Chemie International Edition, Blood and Journal of Medicinal Chemistry.

In The Last Decade

Dramane I. Lainé

28 papers receiving 519 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dramane I. Lainé United States 14 238 193 114 111 69 29 528
Paolo Di Fruscia United Kingdom 10 352 1.5× 332 1.7× 48 0.4× 95 0.9× 56 0.8× 15 980
Michael Härter Germany 10 314 1.3× 176 0.9× 20 0.2× 60 0.5× 42 0.6× 13 595
Fengrong Xu China 15 176 0.7× 203 1.1× 26 0.2× 43 0.4× 26 0.4× 32 456
Robin A. Fairhurst United Kingdom 19 390 1.6× 664 3.4× 247 2.2× 226 2.0× 44 0.6× 49 1.2k
Jenny Viklund Sweden 12 132 0.6× 416 2.2× 35 0.3× 67 0.6× 52 0.8× 15 724
David G. Hulcoop United Kingdom 12 442 1.9× 284 1.5× 30 0.3× 31 0.3× 43 0.6× 20 857
Edward J. Hennessy United States 14 597 2.5× 250 1.3× 23 0.2× 42 0.4× 93 1.3× 21 853
Roy K. Hom United States 10 134 0.6× 225 1.2× 32 0.3× 158 1.4× 35 0.5× 15 530
Robert T. Lum United States 16 329 1.4× 332 1.7× 29 0.3× 24 0.2× 93 1.3× 19 759
Christopher M. Tegley United States 17 290 1.2× 255 1.3× 30 0.3× 20 0.2× 28 0.4× 22 667

Countries citing papers authored by Dramane I. Lainé

Since Specialization
Citations

This map shows the geographic impact of Dramane I. Lainé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dramane I. Lainé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dramane I. Lainé more than expected).

Fields of papers citing papers by Dramane I. Lainé

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dramane I. Lainé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dramane I. Lainé. The network helps show where Dramane I. Lainé may publish in the future.

Co-authorship network of co-authors of Dramane I. Lainé

This figure shows the co-authorship network connecting the top 25 collaborators of Dramane I. Lainé. A scholar is included among the top collaborators of Dramane I. Lainé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dramane I. Lainé. Dramane I. Lainé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Atallah, Ehab, Michael J. Mauro, Koji Sasaki, et al.. (2024). Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial. Future Oncology. 20(38). 3065–3075. 7 indexed citations
2.
3.
Burnett, Arthur L., Fuad El Rassi, Deepika S. Darbari, et al.. (2020). 147 A Prospective Phase II, Open-Label, Single-arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients With Priapism (SPARTAN). The Journal of Sexual Medicine. 17(Supplement_1). S43–S43.
4.
Shah, Nirmish, Ralph V. Boccia, Walter K. Kraft, et al.. (2019). PRO3 SUCCESSOR STUDY: TREATMENT AND HEALTH CARE RESOURCE UTILIZATION BY SICKLE CELL PATIENTS WHO PARTICIPATED IN THE SUSTAIN STUDY IN THE UNITED STATES. Value in Health. 22. S335–S335. 3 indexed citations
5.
Phillips, Jonathan E., Paul G. Harris, Ruoqi Peng, et al.. (2016). Btk Inhibitor RN983 Delivered by Dry Powder Nose-only Aerosol Inhalation Inhibits Bronchoconstriction and Pulmonary Inflammation in the Ovalbumin Allergic Mouse Model of Asthma. Journal of Aerosol Medicine and Pulmonary Drug Delivery. 29(3). 233–241. 14 indexed citations
6.
Chen, Mao Xiang, Emma Ward, Helen F. Sneddon, et al.. (2014). Validation and Optimization of Novel High-Throughput Assays for Human Epithelial Sodium Channels. SLAS DISCOVERY. 20(2). 242–253. 8 indexed citations
7.
Salmon, M, Mark A. Luttmann, James J. Foley, et al.. (2013). Pharmacological Characterization of GSK573719 (Umeclidinium): A Novel, Long-Acting, Inhaled Antagonist of the Muscarinic Cholinergic Receptors for Treatment of Pulmonary Diseases. Journal of Pharmacology and Experimental Therapeutics. 345(2). 260–270. 64 indexed citations
8.
Lainé, Dramane I., Mark A. Luttmann, James J. Foley, et al.. (2011). The pre-clinical pharmacology of the inhaled muscarinic antagonist GSK573719 predicts once-daily clinical dosing. European Respiratory Journal. 38(Suppl 55). 3450–3450. 15 indexed citations
9.
Busch‐Petersen, Jakob & Dramane I. Lainé. (2011). Inhaled Long-Acting Muscarinic Antagonists in Chronic Obstructive Pulmonary Disease. Future Medicinal Chemistry. 3(13). 1623–1634. 8 indexed citations
10.
Lainé, Dramane I. & Jakob Busch‐Petersen. (2010). Inhibitors of cathepsin C (dipeptidyl peptidase I). Expert Opinion on Therapeutic Patents. 20(4). 497–506. 35 indexed citations
11.
Wan, Zehong, Dramane I. Lainé, Hongxing Yan, et al.. (2009). Discovery of (3-endo)-3-(2-cyano-2,2-diphenylethyl)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octane bromide as an efficacious inhaled muscarinic acetylcholine receptor antagonist for the treatment of COPD. Bioorganic & Medicinal Chemistry Letters. 19(16). 4560–4562. 2 indexed citations
12.
Lainé, Dramane I.. (2009). Long-acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease. Expert Review of Clinical Pharmacology. 3(1). 43–53. 9 indexed citations
13.
Lainé, Dramane I., et al.. (2009). Synthesis of the non-adjacent bis-THF core of cis-sylvaticin using a double oxidative cyclisation. Organic & Biomolecular Chemistry. 7(5). 1017–1017. 10 indexed citations
14.
Wang, Yonghui, Feng Wang, Haibo Xie, et al.. (2009). M3 muscarinic acetylcholine receptor antagonists: SAR and optimization of bi-aryl amines. Bioorganic & Medicinal Chemistry Letters. 19(6). 1686–1690. 4 indexed citations
15.
Lainé, Dramane I., Zehong Wan, Hongxing Yan, et al.. (2009). Design, Synthesis, and Structure−Activity Relationship of Tropane Muscarinic Acetylcholine Receptor Antagonists. Journal of Medicinal Chemistry. 52(16). 5241–5252. 9 indexed citations
16.
Angell, Richard, Paul Bamborough, Jacky B. Buckton, et al.. (2008). Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity. Bioorganic & Medicinal Chemistry Letters. 18(15). 4428–4432. 63 indexed citations
17.
Angell, Richard, Paul Bamborough, Mark J. Bamford, et al.. (2008). Biphenyl amide p38 kinase inhibitors 4: DFG-in and DFG-out binding modes. Bioorganic & Medicinal Chemistry Letters. 18(15). 4433–4437. 52 indexed citations
18.
Adderley, Nicola J., et al.. (2003). Highly Diastereoselective Oxy‐Michael Additions of Enantiopure δ‐Lactol Anions to Nitroalkenes: Asymmetric Synthesis of 1,2‐Amino Alcohols. Angewandte Chemie International Edition. 42(35). 4241–4244. 50 indexed citations
19.
Dixon, Darren J., et al.. (2003). Short asymmetric syntheses of bioactive β-aryl ethanolamine derivatives via the highly diastereoselective delta lactol oxy-Michael addition. Tetrahedron Asymmetry. 15(2). 195–197. 15 indexed citations
20.
Hu, Yulai, et al.. (2002). . Angewandte Chemie. 114(18). 3629–3630. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Paolo Di Fruscia Breakdown of academic impact, for papers by Michael Härter Breakdown of academic impact, for papers by Fengrong Xu Breakdown of academic impact, for papers by Robin A. Fairhurst Breakdown of academic impact, for papers by Jenny Viklund Breakdown of academic impact, for papers by David G. Hulcoop Breakdown of academic impact, for papers by Edward J. Hennessy Breakdown of academic impact, for papers by Roy K. Hom Breakdown of academic impact, for papers by Robert T. Lum Breakdown of academic impact, for papers by Christopher M. Tegley
Rankless by CCL
2026